Clinical Trial Update: A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses the efficacy and safety of Afimkibart (RO7790121) in participants with moderate to severe atopic dermatitis and is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Afimkibart (RO7790121)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Atopic Dermatitis | Phase 2 | Status: RECRUITING